Compare ANIX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | AMWL |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.5M | 91.2M |
| IPO Year | 2013 | 2020 |
| Metric | ANIX | AMWL |
|---|---|---|
| Price | $3.52 | $11.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.67 | $7.40 |
| AVG Volume (30 Days) | ★ 300.9K | 147.3K |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 57.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $3.71 |
| 52 Week High | $5.46 | $13.45 |
| Indicator | ANIX | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 56.91 |
| Support Level | $2.48 | $4.49 |
| Resistance Level | $3.53 | $13.45 |
| Average True Range (ATR) | 0.29 | 0.96 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 59.13 | 51.05 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.